# A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

> **NCT05353205** · PHASE4 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- CML, Chronic Phase

## Interventions

- **DRUG:** Flumatinib mesylate tablets (400mg)
- **DRUG:** Flumatinib mesylate tablets (600mg)

## Key facts

- **NCT ID:** NCT05353205
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-23
- **Primary completion:** 2022-12-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05353205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05353205, "A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05353205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*